AC Immune (NASDAQ:ACIU) Releases Earnings Results, Beats Expectations By $0.01 EPS

AC Immune (NASDAQ:ACIU) announced its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01, FiscalAI reports. The firm had revenue of $1.40 million for the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative return on equity of 103.15% and a negative net margin of 1,977.71%.

AC Immune Stock Performance

AC Immune stock opened at $3.03 on Friday. AC Immune has a fifty-two week low of $1.51 and a fifty-two week high of $4.00. The firm has a market capitalization of $308.36 million, a price-to-earnings ratio of -3.61 and a beta of 1.63. The stock’s fifty day moving average is $2.93 and its two-hundred day moving average is $3.09.

Institutional Investors Weigh In On AC Immune

Several institutional investors and hedge funds have recently made changes to their positions in ACIU. EFG International AG acquired a new stake in AC Immune in the 4th quarter valued at about $41,000. Private Advisor Group LLC acquired a new position in AC Immune during the third quarter worth about $48,000. Sei Investments Co. purchased a new stake in shares of AC Immune in the second quarter valued at about $51,000. Goldman Sachs Group Inc. lifted its holdings in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of AC Immune in the third quarter valued at approximately $63,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on ACIU shares. Wall Street Zen upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a report on Monday, April 20th. Jefferies Financial Group reiterated a “buy” rating and issued a $7.00 price objective on shares of AC Immune in a research note on Friday, March 13th. Finally, BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of AC Immune in a report on Monday, March 16th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.50.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.